China’s 2024 Negative List Eases Restrictions on Foreign Investment in TCM and Biotechnology
The National Development and Reform Commission (NDRC) of China has announced the release of the...
China’s NMPA Proposes Inclusion of Cochlear Implants in Volume-Based Procurement Plans
The National Medical Products Administration (NMPA) has disclosed plans to expand the scope of its...
Edwards Lifesciences Sells ICU Business to BD in $4.2 Billion Deal, Announces Layoffs
Edwards Lifesciences, a leading U.S. medical device company, has reportedly reached an agreement to sell...
Zelgen Biopharma’s ZG006 Shows Promising Anti-Tumor Efficacy in Phase I/II SCLC Study
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...
China’s NHSA Proposes New Guidelines to Enhance Oversight of Medical Insurance Funds
The National Healthcare Security Administration (NHSA) has unveiled a draft of the “Guiding Opinions on...
Caprico Biotechnologies and Mindray Medical Form Comprehensive Flow Testing Partnership
Caprico Biotechnologies, Inc., a Chinese biotechnology company, has entered into a comprehensive partnership with Mindray...
China Opens Doors to Foreign Biotech and Wholly-Owned Hospitals in Healthcare Sector Expansion
China’s Ministry of Commerce, National Health Commission, and National Medical Products Administration (NMPA) have jointly...
Connect Biopharma Shifts Focus to US, Plans Further Reduction in China Workforce
Connect Biopharma Holdings Ltd (NASDAQ: CNTB), a Sino-US biotechnology company that initially operated in Suzhou...
Guangzhou Health Commission Unveils Ten Measures to Boost Innovative Pharma and Medical Device Development
On September 5, 2024, the Guangzhou Health Commission issued the “Guangzhou Health Commission’s Ten Measures...
Merck and Daiichi Sankyo’s Ifinatamab Deruxtecan Shows Promising Results in Phase II ES-SCLC Trial
Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK), a leading U.S. pharmaceutical company, and its...
Biosecure Act Faces Opposition from Senior House Democrat Jim McGovern
The trajectory of the US Biosecure Act through the House of Representatives encountered unexpected turbulence...
China’s CDE Releases 86th Batch of Reference Preparations for Generic Drug Evaluation
China’s Center for Drug Evaluation (CDE) has unveiled its 86th roster of reference preparations for...
Akeso’s Ivonescimab Shows Promising Results in Phase III Clinical Trial for Hepatocellular Carcinoma
Akeso Inc. (HKG: 9926), a biopharmaceutical company based in China, has announced that its first-in-class...
AstraZeneca Faces Investigation in China Over Data Privacy and Unapproved Drugs
AstraZeneca (NASDAQ: AZN), a leading UK pharmaceutical company, is reportedly under the spotlight in Shenzhen,...
U.S. House of Representatives to Review the Biosecure Act Amid Legislative Hurdles
The U.S. House of Representatives is slated to take up the contentious Biosecure Act the...
Eli Lilly Partners with Genetic Leap for RNA-Targeted AI Drug Discovery
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the U.S., has...
Euroapi to Downsize API Production, Citing Asian Competition and Market Stagnation
Euroapi (EPA: EAPI), a French company and a spinoff from Sanofi established in 2022, has...
Rigel Pharmaceuticals Strikes Deal with Kissei for Development and Commercialization of Rezlidhia in East Asia
Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), a biopharmaceutical company based in the U.S., has entered into...
Sinocelltech’s Herpes Zoster Vaccine SCTV04C Clears NMPA for Clinical Trial
Sinocelltech Group Ltd (SHA: 688520), a biopharmaceutical company based in China, has received approval from...
Voyager Therapeutics Secures Licensing Deal with Novartis for Gene Therapy Capsid
Voyager Therapeutics Inc. (NASDAQ: VYGR), a U.S.-based biotechnology company, has announced a licensing agreement with...